mrd testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trials
Published 4 months ago • 213 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
1:38
using mrd as an endpoint in clinical trials
-
1:18
standardizing mrd techniques after fda approval as a surrogate endpoint in myeloma trials
-
1:31
mrd as an endpoint in clinical trials
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
1:11:05
the utility of mrd testing for myeloma patient treatment and outcomes
-
2:09
mrd in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisions
-
4:44
minimal residual disease (mrd) | high impact topic (hit)
-
10:52
what are some possible uses of mrd testing?
-
4:54
does everyone need to become mrd negative to have good outcomes?
-
1:49
key challenges that remain in the diagnosis of al amyloidosis
-
1:46
standardization mrd monitoring in clinical trials
-
7:01
is mrd testing a standard of care?
-
2:31
determining the optimal threshold to test mrd in multiple myeloma
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
2:27
milestone trial results: mrd response-adapted deferral of autosct in newly diagnosed myeloma
-
2:17
opinion: value of mrd as an endpoint in hem-onc clinical trials
-
1:00
mrd as a response assessment in elderly multiple myeloma
-
5:44
can mrd testing be done on a blood sample?
-
0:59
opinion: mrd sequencing test approval in multiple myeloma
-
1:20
mrd in myeloma
-
5:18
response monitoring in multiple myeloma